Sangamo Therapeutics Inc (LTS:0R1D)
$ 2.18 -0.06 (-2.68%) Market Cap: 492.41 Mil Enterprise Value: 480.93 Mil PE Ratio: 0 PB Ratio: 12.55 GF Score: 41/100

Sangamo Therapeutics Inc at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript

Nov 16, 2020 / 03:45PM GMT
Release Date Price: $10.43
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Welcome, everyone. My name is Gena Wang. I'm SMid Cap biotech analyst at the Barclays. It's my great pleasure to introduce our next presenting company, Sangamo Therapeutics.

On the call with me, we have Sandy Macrae, President and Chief Executive Officer; Sung Lee, Chief Financial Officer; and Aaron Feingold, Head of Corporate Communications.

With that, I hand over to you, Sandy.

Alexander D. Macrae
Sangamo Therapeutics, Inc. - CEO, President & Director

Thank you, Gena. And let me share my slide, share my screen. It's wonderful how we've all become our own tech in these days.

So Gena, thank you very much for having us. It's a real pleasure to be here. I'll just get rid of this. So I want to talk to you about Sangamo. And of course, during today's presentation, I'll be making forward-looking statements, so please refer to our releases filings with the SEC.

We're Sangamo Therapeutics. And for us, it's about translating our groundbreaking science into

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot